Clinical Drug Insights
Anticoagulant Side Effects: Bleeding Risk Compared
Anticoagulant side effects compared across warfarin and DOACs, sourced from meta-analyses of bleeding risk, plus India's NLEM and monitoring requirements.
The Medyzen blog
Clinical Drug Insights
Anticoagulant side effects compared across warfarin and DOACs, sourced from meta-analyses of bleeding risk, plus India's NLEM and monitoring requirements.
Clinical Drug Insights
Why warfarin still outperforms DOACs for rheumatic heart disease in India, dabigatran's cost-effectiveness gap, and anticoagulant availability hospital pharmacy planning.
Clinical Drug Insights
A clinical overview of anticoagulant India options: warfarin, heparins and DOACs, their indications, monitoring needs, and essential-medicines status.
Clinical Drug Insights
Anticoagulant drug interactions with NSAIDs, antibiotics, antiepileptics and herbal supplements, sourced from PubMed, NIH and clinical case reports.
Clinical Drug Insights
Real anticoagulant cost variation across brands in India, NPPA price control status, and Jan Aushadhi generic pricing, sourced from published data.

Clinical Drug Insights
An anticoagulant comparison of warfarin against DOACs (dabigatran, rivaroxaban, apixaban): efficacy, bleeding profile, monitoring needs and NLEM status in India.
Clinical Drug Insights
How antibiotic resistance is tracked in India, which pathogens and drug classes are most affected, and what it means for hospital prescribing and stocking.

Costs & Economics
Gross margins look healthy — but after staffing, expiry, and locked capital, what does a hospital pharmacy really keep? The honest numbers.